NCT06842927 (DETECT-PD) is a clinical trial of data collection in End-Stage Kidney Disease, sponsored by Tuen Mun Hospital.

Who is sponsoring NCT06842927?

NCT06842927 is sponsored by Tuen Mun Hospital.

What drugs are being tested in NCT06842927?

Interventions in NCT06842927: data collection, data report.

What condition does NCT06842927 study?

NCT06842927 studies End-Stage Kidney Disease, End Stage Renal Disease (ESRD), End Stage Renal Disease on Dialysis (Diagnosis), End Stage Renal Failure on Dialysis, Peritoneal Dialysis, Peritoneal Dialysis Patients.

Is NCT06842927 still recruiting?

NCT06842927 is currently enrolling by invitation. Last updated 9 April 2025.

Last reviewed 2025-04-09 · How we verify

NCT06842927: DETECT-PD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dialysis Efficiency and Transporter Evaluation Computational Tool in Peritoneal Dialysis

ENROLLING BY INVITATION Last updated 9 April 2025

What this trial tests

trial testing data collection in End-Stage Kidney Disease in 350 participants. Enrolling by invitation.

Timeline

3 March 2025

Primary endpoint
28 February 2026

31 March 2026

Quick facts

Lead sponsor	Tuen Mun Hospital
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	350
Start date	3 March 2025
Primary completion	28 February 2026
Estimated completion	31 March 2026
Sites	1 location across Hong Kong

Drugs / interventions tested

data collection — full drug profile →
data report — full drug profile →

Conditions studied

End-Stage Kidney Disease — all drugs for End-Stage Kidney Disease →
End Stage Renal Disease (ESRD) — all drugs for End Stage Renal Disease (ESRD) →
End Stage Renal Disease on Dialysis (Diagnosis) — all drugs for End Stage Renal Disease on Dialysis (Diagnosis) →
End Stage Renal Failure on Dialysis — all drugs for End Stage Renal Failure on Dialysis →

Sponsor

Tuen Mun Hospital

Who can join

18 and older, any sex, with End-Stage Kidney Disease or End Stage Renal Disease (ESRD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this prospective diagnostic test (correlation) study is to develop and investigate the performance of artificial intelligence in predicting peritoneum transporter status and dialysis efficiency in adult patients undergoing peritoneal dialysis (PD). The main questions it aims to answer are: Can artificial intelligence predict peritoneal transporter status based on simple clinical and biochemical measurements? Can artificial intelligence predict dialysis adequacy (Kt/V) using these features? Researchers will compare the performance of the AI model with the gold standard Peritoneal Equilibration Test (PET) and Kt/V to evaluate its accuracy and reliability. Participants will: Provide peritoneal dialysate and spot urine samples for biochemical analysis. Undergo routine dialysis adequacy and peritoneal equilibration testing (PET). Have clinical and laboratory data collected for AI model training and validation. The study will recruit approximately 350 peritoneal dialysis patients, with 280 participants in the training/validation arm and 70 participants in the test arm. The study duration is 12 months following enrollment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of data collection

Trials testing the same drug.

NCT07437495 — Women's Knowledge of Contraception During the Postpartum Period · active not recruiting
NCT07424937 — Prevalence of Regular Gynecological Follow-up Among Women of Childbearing Age · completed
NCT07440082 — Resumption of Sexual Intercourse in the Postpartum Period: Women's Experiences · completed
NCT07241299 — Understanding Chronic Treatments by Patients Over 65 Years of Age · recruiting
NCT07338955 — Validating and Assessing Reliability · recruiting

Other recruiting trials for End-Stage Kidney Disease

Currently open trials in the same condition.

NCT06700876 — Evaluation of IGRA, Symptoms and Chest Radiograph for Subclinical TB Detection in ESRD and KT · recruiting
NCT05931276 — CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes · Phase 3 · recruiting
NCT04646226 — The Arteriovenous Vascular (AV) ACCESS Trial · NA · active not recruiting
NCT05449067 — Comparison of Efficacy Between Nighttime and Daytime Peritoneal Dialysis · NA · recruiting

Other Tuen Mun Hospital trials

Trials by the same sponsor.

NCT07293468 — Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH) · Phase 2, PHASE3 · recruiting
NCT05796076 — Virtual Reality to Reduce Anxiety and Pain During Suturing Procedure · NA · completed
NCT05182203 — Safety and Retention Rate of the JAK and TNF Inhibitors in Rheumatoid Arthritis: a Real-life Experience · completed
NCT04091243 — Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users · Phase 4 · completed
NCT04388553 — Single Shot Lumbar Erector Spinae Plane (ESP) Block in Total Hip Replacement (THR) · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06842927 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tuen Mun Hospital
Last refreshed: 9 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06842927.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing